DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0269704 A1 Seigfried (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0269704 A1 Seigfried (43) Pub US 20110269.704A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0269704 A1 Seigfried (43) Pub. Date: Nov. 3, 2011 (54) METHOD FOR DEVELOPING ALIQUID A6IP 23/02 (2006.01) COMPOSITION TO BEAPPLIED TO THE A6II 3/196 (2006.01) SKNASA FOAMAND ACOMPOSITION A6IP 29/00 (2006.01) THAT CAN BE APPLIED TOPCALLY A6IP3L/00 (2006.01) A6IP3L/04 (2006.01) (76) Inventor: Bernd G. Seigfried, Limburgerhof A63L/92 (2006.01) (DE) A6II 3/474 (2006.01) (21) Appl. No.: 13/143,740 (52) U.S. Cl. ........... 514/29: 514/570; 514/626; 514/179; 514/396; 514/567 (22) PCT Filed: Jul. 16, 2010 (86). PCT No.: PCT/DE2O1 O/OOO818 (57) ABSTRACT A liquid pharmaceutical composition to be applied to the skin S371 (c)(1), as a foam and that has at least one solvent, at least one active (2), (4) Date: Jul. 8, 2011 pharmaceutical ingredient, and at least one foaming agent. The foam volume and the foam stability are determined (30) Foreign Application Priority Data according to a standardized SITA measuring method. The foaming agent, the solvent, and the active pharmaceutical Jul. 24, 2009 (DE) ...................... 10 2009 O34 603.1 ingredient are varied in regard to the chemical type and/or concentration thereof until the foam thus produced by the Publication Classification SITA measuring method has a foam volume of at least 400 ml (51) Int. Cl. and such foam stability that after a dwell time of up to ten A6 IK3I/7048 (2006.01) minutes the foam still has at least 50% of the foam volume A6 IK3I/I67 (2006.01) that originally existed immediately after the foam was pro A 6LX 3/573 (2006.01) duced. Patent Application Publication Nov. 3, 2011 Sheet 1 of 18 US 2011/0269.704 A1 12OO 1OOO 800 run----------------as-s-s-s-s-s-s-s-s-s E -- 1st measurement E 600 i -- 2: 83.Stiteriesav 3ri eastesses s E 400 es S 2OO O O.O 5.0 1O.O 15.0 2O.O 25.0 3O.O. 35.0 time (min) Figure 1 Patent Application Publication Nov. 3, 2011 Sheet 2 of 18 US 2011/0269.704 A1 12OO OOO re-t-to----- -- ist measurement 3rd easiest 8OO is essesses S 6OO S Eg E 4OO t S 2OO O O.O 5.0 O.O 15.O 2O.O 25.0 3OO 35.0 time (min) Figure 2 Patent Application Publication Nov. 3, 2011 Sheet 3 of 18 US 2011/0269.704 A1 12OO 1OOO 8OO wn. S. 6OO -- 1st measurement -- ci easterest 400 a 3rd measurement e : E s O *H 200 O O.O 5.0 1O.O. 150 2O.O 25.O. 3O.O 35.O time (min) Figure 3 Patent Application Publication Nov. 3, 2011 Sheet 4 of 18 US 2011/0269.704 A1 1200 1000 SOO St SeaStreet was 2d easurement a 3rd measurement O.O 5.O 1O.O 15.O 2O.O 25.0 3O.O 35.0 time (min) Figure 4 Patent Application Publication Nov. 3, 2011 Sheet 5 of 18 US 2011/0269.704 A1 1200 1OOO 8OO 1st measurement g was 2nd reasurement ''d 600 -- 3rd3. measurement3S S 400 --- s O 2OO O O.O 5.0 10.0 15.O. 2O.O 25.0 3O.O 35.0 time (min) FigureiOIIIA 5is Patent Application Publication Nov. 3, 2011 Sheet 6 of 18 US 2011/0269.704 A1 12OO 1OOO 800 o 6OO -- St SeaStreite was 2nd measurement : 4OO was 3' east eiteit 9 2OO O O.O 5.0 1O.O 150 2O.O 25.O 3O.O 35.0 time (min) Figure 6 Patent Application Publication Nov. 3, 2011 Sheet 7 of 18 US 2011/0269.704 A1 1200 1OOO 8OO a 600 co------------ist easiere area is feasiefet oe 400 wa.-- 3rds f{ measurementi &isie & S. 2OO O O.O. 5.O. 1O.O 15.O. 2O.O 25.0 3.O.O 35.O time (min) Figure 7 Patent Application Publication Nov. 3, 2011 Sheet 8 of 18 US 2011/0269.704 A1 12OO 1OOO 8OO -- ist measurement was 2 easisi seriest E 600 | -- 3rd- - measurementcasus is is E Eg E 4OO r 9 2OO O O.O. 5.O 1O.O 15.O 2O.O 25.0 3O.O 35.O time (min) Figure 8 Patent Application Publication Nov. 3, 2011 Sheet 9 of 18 US 2011/0269.704 A1 1400 1200 OOO - 2nd measurement 6OO ... 3rd yeastfeet g 400 S 2OO O O.O 5.O 1O.O 15.0 O.O 25.0 3O.O 35.0 time (min) Figure 9 Patent Application Publication Nov. 3, 2011 Sheet 10 of 18 US 2011/0269.704 A1 12OO 1OOO 800 E 600 ~~~~~~~~~-- 1st measurement | -- 2: Yeastesters s 400 is...was...........:-- 3rd measurement es S 2OO O O.O 5.0 1O.O 15.O 2O.O. 25.0 3O.O 35.0 time (min) Figure 10 Patent Application Publication Nov. 3, 2011 Sheet 11 of 18 US 2011/0269.704 A1 1200 1OOO ... is easietet x - 2c teasefiest 3' sease et 8OO -- S 600 4 O O 2OO O O.O 5.0 1O.O 15.0 2O.O 25.O 3O.O. 35.0 time (min) Figure 11 Patent Application Publication Nov. 3, 2011 Sheet 12 of 18 US 2011/0269.704 A1 12OO OOO 800 =:::::::::::::::::::::::::= S. w 600 i -- 1st measurement E -- 388 iéaSietet Oce ... 3: Seasierest 400 : s t 3 2OO O O.O 5.O 1O.O. 15.O. 2O.O. 250 3OO 350 time (min) Figure 12 Patent Application Publication Nov. 3, 2011 Sheet 13 of 18 US 2011/0269.704 A1 12OO OOO 800 -- is easiest s -- 28 seasteries: E six 3 easiliesert 600 - -...................... E E g 400 E 9es S. 2OO O O.O 50 1O.O 15.O. 2O.O 25.O 30.0 35. time (min) Figure 13 Patent Application Publication Nov. 3, 2011 Sheet 14 of 18 US 2011/0269.704 A1 12OO 1OOO FrrarierRealeries-le-a==as-s-s-s 8OO f S 6OO | -- 1st measurement E saw is easiere g 400 ... 3ic east see S. 2OO O l O.O 5.O 1O.O 15.O 2O.O 25.O 3O.O 35.O time (min) Figure 1-4 Patent Application Publication Nov. 3, 2011 Sheet 15 of 18 US 2011/0269.704 A1 12OO OOO 8OO 600 is ist measurement E E ene 2c feasiertei g was 3' easterest E 400 i. s S. 2OO O O.O 5.0 1O.O 15.O 2O.O 25.O 3O.O 35.0 time (min) Figure 15 Patent Application Publication Nov. 3, 2011 Sheet 16 of 18 US 2011/0269.704 A1 12OO 1OOO 8OO g 600 -- is measurerrent were 2 &as 88. g 400 x 3x seases: make it easiester S. were it 2OO Wana O O.O 5.0 1 O.O. 15.0 2O.O. 25.0 3O.O. 35.0 time (min) Figure 16 Patent Application Publication Nov. 3, 2011 Sheet 17 of 18 US 2011/0269.704 A1 12OO 1OOO 8OO F or a 600 is is assireiteit 5 -- 3: easterest g ss. 3 seasis'éties 400 . t S 2OO O O.O 5.O 1O.O 15.0 2O.O 25.0 3O.O 35.0 time (min) Figure 17 Patent Application Publication Nov. 3, 2011 Sheet 18 of 18 US 2011/0269.704 A1 1200 1OOO S 600 -- is east resert 5 -- 3rd easterest eo 400 sa. 3's1&S easierest r S 2OO O O.O 5.O 1O.O 15.O 2O.O 25.O 3O.O 35.O time (min) Figure 18 US 2011/0269.704 A1 Nov. 3, 2011 METHOD FOR DEVELOPING ALIQUID sive and may suffer from a drawback such that a foam differ COMPOSITION TO BE APPLIED TO THE ing in composition and essentially inhomogeneous can result SKNASA FOAMAND A COMPOSITION from varying the configuration of the aforementioned param THAT CAN BE APPLIED TOPCALLY eters of the mechanical foam applicator. 0008 Thus, one underlying problem of the present inven tion is to provide a method for the development of a liquid 0001. The present invention is directed in part to a method pharmaceutical composition to be applied as foam to the skin, for making or developing liquid pharmaceutical composi by which the development time for such pharmaceutical com tions to be applied as a foam to the skin with the features of the positions is Substantially simplified and shortened. preamble of the patent claim 1 as well as a corresponding 0009 Further, another underlying problem of the present topically applicable compositions with the features of the invention is to provide a topically applicable composition that preamble of the patent claim 9. can be applied as foam and that contains a systemically or 0002 Topically applied pharmaceutical compositions that topically acting pharmaceutical active ingredient, whereby exist in the liquid state and are present as a foam when applied this topically applicable composition is developed preferably are familiar. For example, EP 0510561 B1 describes one by the aforementioned development process. Such pharmaceutical composition applied as foam, wherein 0010. The first stated problem is solved by a method the basic liquid used in the known pharmaceutical composi according to the characteristics of the patent claim 1 and the tion is foamed exclusively by mechanical action. The basic further problem, which is mentioned subsequently, is solved liquid composition that is mechanically foamed contains, as by a topically applicable composition with the features of the ingredients, a surfactant as the foaming agent, a solvent or preamble of the patent claim 9.
Load more

Recommended publications
  • In Cooperation with Proficiency Test 8/18 TW S6 – X-Ray- and MRT-Contrast Media in Drinking Water Dear Madam Or Sir, In
    Institute for Sanitary Engineering, Water Quality and Solid Waste Management AQS Baden-Württemberg Universit y of Stuttgart ● ISWA ● Bandtäle 2 ● 70569 Stuttgart Contact person AQS Baden-Württemberg Dr. Frank Baumeister, Dr. Michael Koch, Mandy Wünsche To the participants of AQS Baden-Württemberg Contact details Bandtäle 2 70569 Stuttgart GERMANY T +49 711 685-65446 F +49 711 685-63769 [email protected] www.aqsbw.de Proficiency test 8/18 TW S6 – X-ray- and MRT-contrast media in drinking water 2018-06-22 Dear Madam or Sir, in September 2018 the execution of the above mentioned proficiency test (PT) round „X-ray- and MRT-contrast media in drinking water” is planned. The PT is carried out under the umbrella of the NORMAN Network of Reference Laboratories for Monitoring of Emerging Environmental Pollutants (http://www.norman-network.net) in cooperation with IWW Water Centre. Details about the PT round are enclosed. Please read them with care. If you are interested in participation, please register online via our website http://www.iswa.uni-stuttgart.de/ch/aqs/rv/anm_rv.en.php?id=181. You will receive a confirmation of receipt by e-mail. With a second e- mail we will bindingly confirm your application to the PT. You are not registered if you do not receive any e-mail. Application deadline: 24 July 2018 Please consider our general terms and conditions of business for the execution of the PT, which can be downloaded from http://www.aqsbw.de/pdf/agb_en.pdf. Bank Baden-Württembergische If we receive your application after the deadline we cannot guarantee Bank Stuttgart – BW-Bank that participation will be possible.
    [Show full text]
  • Published Version
    Chapter 12 Water quality analysis: Detection, fate, and behaviour, of selected trace organic pollutants at managed aquifer recharge sites Mathias Ernst, Arne Hein, Josef Asmin, Martin Krauss, Guido Fink, Juliane Hollender, Thomas Ternes, Claus Jørgensen, Martin Jekel and Christa S. McArdell 12.1 INTRODUCTION In treated municipal wastewater, residual organic compounds are of high relevance especially if water recycling and potable water reuse is envisaged. After biological treatment, such as the activated sludge process, some organic compounds remain that are either non-biodegradable, or are minimally biodegradable. If these chemicals are polar, they are commonly poorly absorbable, and are therefore identified as persistent polar organic compounds (also persistent polar pollutants, PPPs). In the last decade, there have been important analytical improvements in detecting trace levels of pollutants, and within the water reuse community, new “hazardous” compounds are frequently discussed. This includes consideration of which organic residuals are really of health concern, which transformation products can be generated, and what is their human and environmental impact? Within the present chapter relevant PPPs and their fate during (advanced) wastewater treatment and managed aquifer recharge are identified and discussed as results of measuring campaigns at technologically different demonstration sites within the European research project RECLAIM WATER. Such PPPs mainly belong in the group of pharmaceuticals but also industrial chemicals. Here antibiotics such as the macrolides and sulfonamides are of particular concern, because of the eco-toxicological potential of these parent micropollutants, and the potential threat posed by the build-up of antibiotic resistance genes. In addition to known multi-resistant bacteria such as Staphylococci, multi-resistant genes have recently been identified in the intestinal bacteria Citrobacter, Enterobacteriaceae and Escherichia coli (Patoli et al.
    [Show full text]
  • 201277Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201277Orig1s000 OTHER REVIEW(S) PMR/PMC Development Template This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package. PMR/PMC Description: DARRTS Set #1743-1 A study that will examine the safety of Gadavist in new born and neonates animals, following a single dose and limited repeated dose administrations. The study will provide safety data assessing mortality, toxicities, and potential reversibility of observed clinical and histopathological findings. The study will also examine the pharmacokinetics of Gadavist including tissue deposition of Gadolinium. PMR/PMC Schedule Milestones: Final Protocol Submission: May, 2011 Study/Trial Completion: January, 2012 Final Report Submission: June, 2012 Other: 1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe. Unmet need Life-threatening condition Long-term data needed Only feasible to conduct post-approval (I removed this check on the nonclinical form) Prior clinical experience indicates safety Small subpopulation affected (I removed this check on the nonclinical form) Theoretical concern Other Proposed nonclinical study will evaluate the safety of Gadavist in a non clinical animal model prior to clinical exposure in view of known risk of NSF in adults especially those with renal impairment. 2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.” ReferencePMR/PMC ID: 2918081Development Template Last Updated 3/14/2011 Page 1 of 4 To evaluate the safety of Gadavist in newborn and neonate animals.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Imaging Diagnostics by Combining Contrast Agents
    (19) TZZ Z _T (11) EP 2 907 526 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.08.2015 Bulletin 2015/34 A61K 49/04 (2006.01) A61K 51/04 (2006.01) A61K 49/06 (2006.01) (21) Application number: 15155866.5 (22) Date of filing: 20.06.2008 (84) Designated Contracting States: (72) Inventor: Wiebelitz, Ulrike AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 13158 Berlin (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Kilger, Ute Boehmert & Boehmert (30) Priority: 22.06.2007 EP 07110922 Anwaltspartnerschaft mbB Patentanwälte Rechtsanwälte (62) Document number(s) of the earlier application(s) in Pettenkoferstrasse 20-22 accordance with Art. 76 EPC: 80336 München (DE) 12199299.4 / 2 572 735 12168380.9 / 2 514 442 Remarks: 08774183.1 / 2 170 405 This application was filed on 20-02-2015 as a divisional application to the application mentioned (71) Applicant: mivenion GmbH under INID code 62. 10115 Berlin (DE) (54) Imaging diagnostics by combining contrast agents (57) The present invention relates to the use of a combination of several contrast agents having different imaging properties with respect to imaging representation. EP 2 907 526 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 907 526 A1 2 Description from suspect lesions and to prepare and assess these samples histopathologically. [0001] The present invention relates to the use of a [0005] MRI examination of the female breast has very combination of several contrast agents having different high sensitivity in comparison to other imaging modali- imaging properties.
    [Show full text]
  • Guideline on Core Smpc and Package Leaflet for Gadoteric Acid EMA/CHMP/337820/2016 Page 2/23
    1 26 May 2016 2 EMA/CHMP/337820/2016 3 Committee for Medicinal Products for Human Use (CHMP) 4 Guideline on core SmPC and Package Leaflet for gadoteric 5 acid 6 Draft Draft agreed by Radiopharmaceutical Drafting Group April 2016 Adopted by CHMP for release for consultation 26 May 2016 Start of public consultation 1 June 2016 End of consultation (deadline for comments) 30 September 2016 7 Comments should be provided using this template. The completed comments form should be sent to [email protected]. 8 Keywords Magnetic resonance, contrast media, gadolinium compounds, core SmPC, core Package Leaflet, gadoteric acid 9 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 10 Guideline on core SmPC and Package Leaflet for gadoteric 11 acid 12 Table of contents 13 Executive summary ..................................................................................... 3 14 1. Introduction (background) ...................................................................... 3 15 2. Scope....................................................................................................... 3 16 3. Legal basis .............................................................................................. 3 17 4. Core SmPC and Package Leaflet for gadoteric acid .................................
    [Show full text]